Skip to main content
Signal8

Seer, Inc. (SEER)

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

Sector: Laboratory Analytical Instruments

Industry: Biotechnology

Seer, Inc. logo

Seer, Inc.

NASDAQ:SEERHealthcare
-13.40%$1.68
AH$1.70+1.19%vs close
Mkt Cap$93.02M
Float32.53M
O/S55.37M
Vol
$ Vol
RVOL
Inst Own37.0%
Earnings
Dilution
Pipeline1 lead-sponsored trial·0 active1 completed(2 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
  • Not applicable
    Completed

    Development of a Minimally Invasive Seizure Gauge

    EpiTel Epilog, Empatica E4

    Epilepsy

    Enrollment
    40
    Start
    Jan 2019
    Primary Completion
    Dec 2023
    Completion
    Dec 2023
    NCT03882671